Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "GPVI" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glycoprotein VI (platelet) also known as GPVI is a glycoprotein receptor for collagen which is expressed in platelets. In humans, glycoprotein VI is encoded by the GPVI gene. GPVI was first cloned in 2000 by several groups including that of Martine Jandrot-Perrus from INSERM.
Methods, products and uses involving platelets and/or the vasculature
InactiveUS20090130021A1Inhibits interactionInhibits GPVI interactionVirusesPeptide/protein ingredientsDiseaseVitronectin
The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI interaction with one or both of fibronectin and vitronectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of GPVI with fibronectin and / or vitronectin are included in the present disclosure. The invention also relates to uses of agents for the prevention or treatment of disorders arising from blood platelet adhesion and aggregation.
Owner:MUNCH GOTZ +5
Nucleic acid modulators of glycoprotein vi
ActiveUS20100311820A1Accelerated destructionReduces eliminates bindingOrganic active ingredientsSenses disorderInduced platelet aggregationCollagen VI
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
Owner:TOBIRA THERAPEUTICS
Aptamers to glycoprotein VI
The present invention relates, in general, to glycoprotein VI (GPVI) and, in particular, to aptamers to GPVI and to compositions comprising same. The invention also relates to methods of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of GPVI. The invention further relates to antidotes to GPVI aptamers and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention also relates to aptamers that bind to and enhance the activity of GPVI.
Owner:DUKE UNIV
Antagonist antibodies and their fab fragments against GPVI and uses thereof
ActiveUS8852593B2Hinder recognitionPrevention of unwanted generation of Fab-antibody complexesPeptide/protein ingredientsGenetic material ingredientsHuman plateletImmunotherapeutic agent
Owner:SANOFI SA
Glycoprotein VI fusion proteins
InactiveUS7507412B2Reduce thrombosisReduce formationOrganic active ingredientsFungiADAMTS ProteinsOligopeptide
Owner:MERCK PATENT GMBH
Anti-human GPVI antibodies and uses thereof
ActiveUS10842870B2Decrease in platelet countNot induce thrombocytopeniaImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesGPVI
Owner:UNIV PARIS SACLAY +3
Fusion protein and its uses
InactiveUS20130108580A1Promote chemotaxisEffective toolSaccharide peptide ingredientsFusions for specific cell targetingDiseaseStromal cell
The present invention relates to a fusion protein comprising a) a first polypeptide selected from among SDF-1 (stromal cell derived factor-1) or peptidase / protease-resistant variants or fragments thereof which have the CXCR4- / CXCR7- binding function of SDF-1; and b) a second polypeptide which is selected from among GPVI (glycoprotein VI), or the extracellular domain of GPVI, or fragments or variants of the extracellular domain of GPVI which contain the collagen binding function of GPVI, wherein the first polypeptide and the second peptide are linked to one another directly or via a linker molecule. The invention furthermore relates to the use of the fusion protein for treating diseases.
Owner:UNIV TUBINGEN
Glycoprotein VI fusion proteins
InactiveUS20080206247A1Improve purification effectProlonged Circulatory Half-LifeAntibacterial agentsOrganic active ingredientsADAMTS ProteinsThrombus
The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-collagen and / or platelet-collagen interaction is disclosed.Further, pharmaceutical compositions and therapeutic methods are provided comprising such GPVI-fusion proteins for the treatment of thrombotic and cardiovascular events and disorders related to GPVI-collagen and / or platelet-collagen interactions.
Owner:BURGER CHRISTA +2
Methods of detection GPVI
InactiveUS8323905B2Peptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseVascular endothelium
Owner:MOCHIDA PHARM CO LTD
Aptamers to glycoprotein vi
ActiveUS20130210903A1High activityInhibits platelet aggregationOrganic active ingredientsSugar derivativesAntidotePlatelet inhibition
The present invention relates, in general, to glycoprotein VI (GPVI) and, in particular, to aptamers to GPVI and to compositions comprising same. The invention also relates to methods of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of GPVI. The invention further relates to antidotes to GPVI aptamers and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention also relates to aptamers that bind to and enhance the activity of GPVI.
Owner:DUKE UNIV
Nucleic acid modulators of glycoprotein VI
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
Owner:TOBIRA THERAPEUTICS
Nucleic acid modulators of glycoprotein VI
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
Owner:TOBIRA THERAPEUTICS
Nucleic acid modulators of glycoprotein vi
ActiveUS20140128454A1Accelerated destructionReduces eliminates bindingOrganic active ingredientsImmunoglobulin superfamilyInduced platelet aggregationCollagen VI
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
Owner:TOBIRA THERAPEUTICS
Uses of a glycoprotein VI (GPVI) inhibitor
Owner:OTSUKA PHARM CO LTD
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
ActiveUS20190315862A1Immunoglobulin superfamilyAntibody mimetics/scaffoldsLymphatic SpreadProphylactic treatment
The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Nucleic acid modulators of glycoprotein VI
ActiveUS8889646B2Organic active ingredientsImmunoglobulin superfamilyInduced platelet aggregationCollagen VI
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
Owner:TOBIRA THERAPEUTICS
Crystal structure of human gpvi and applications thereof
A crystal comprising the collagen binding domain of human GPVI is provided and defined by structural atomic coordinates. Employing computer modeling based on the crystal structure, including methods for identifying inhibitors of GPVI collagen binding activity, methods for screening libraries of compounds for potential to bind to the GPVI collagen binding domain, and methods of identifying a compound useful for the treatment of a GPVI-mediated disorder, are also provided.
Owner:UNIVERSITY OF CINCINNATI
Method and kits for determining platelet susceptibility to activation in a patient
The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
Application of compound in preparation of antithrombotic drugs
ActiveCN114404396AInhibition formationAvoid stickingAldehyde active ingredientsBlood disorderReceptorThrombus
The invention relates to the technical field of medicines, in particular to application of a compound in preparation of antithrombotic drugs. At present, in the preclinical research of new anti-platelet drugs, hemostasis is more and more emphasized while thrombus formation is inhibited. In tMCAO, a receptor GPIb or GPVI which plays a role in the early stage of platelet activation can relieve ischemic brain injury of a mouse, and bleeding complications cannot be increased, so that intervention in the early stage of platelet activation is effective and safer. The compound Col003 is obtained by degrading a natural compound molecule AK778 in a culture medium or a buffer solution, can play an anti-platelet role in the early stage of platelet activation, can inhibit the formation of thrombus, does not affect the blood coagulation function, is relatively weak in cytotoxicity, and is expected to become an effective and safe therapeutic drug for cerebral arterial thrombosis.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV
Human platelet collagen receptor resistant human-derived monoclonal antibody fragment and application thereof
InactiveCN103396492AEliminate the humanization processReduce manufacturing costImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseAntithrombotic Agent
The invention relates to the technical field of biology, also relates to the bio-pharmaceutical technology, and particularly relates to a human platelet collagen receptor ''Glycoprotein VI'' (or GPVI) resistant human-derived monoclonal antibody fragment and application thereof in medicines. The monoclonal antibody fragment is human derived, and comprises polypeptide amino acid sequences comprising three heavy chain variable region HV sequences and three light chain variable region LV sequences, antibody fragment scFv(single chain fragment variable) or other polypeptides recombined by the monoclonal antibody fragment can be used as a blocking agent of collagen receptor ''Glycoprotein VI'' for application in preparation of medicines for treatment or prevention of thrombotic cardio cerebrovascular diseases, the monoclonal antibody fragment can be used in the preparation of antithrombotic medicines resisting collagen to activate platelet, or in the preparation of detection reagents and the like for detecting whether free ''Glycoprotein VI'' exists. In the preparation of the medicines, a very complex humanized reconstruction process is omitted.
Owner:ANHUI NEW MARK SCI TECH
Nucleic acid modulators of glycoprotein vi
ActiveUS20140128587A1Accelerated destructionReduces eliminates bindingSugar derivativesDNA/RNA fragmentationInduced platelet aggregationGlycoprotein
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
Owner:TOBIRA THERAPEUTICS
Antibodies targeting glycoprotein vi
PendingCN112118869AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntibody fragmentsThrombogenicity
Owner:MORFOZIS AG
Primer for detecting methylation level of GPVI gene promoter region and detection method thereof
PendingCN110951866AHigh expressionInhibition of adhesionMicrobiological testing/measurementDNA/RNA fragmentationPromoterBisulfite
The invention discloses a primer for detecting methylation level of a GPVI gene promoter region and a detection method of the primer. The primer comprises an amplification primer pair of the GPVI genepromoter region after bisulfite conversion and a sequencing primer GPVI-S, the sequence of the upstream primer GPVI-F is 5'-ATTAGGGAGTTTATGGGAGTACGG-3', and the sequence of the downstream primer GPVI-R is 5'-Biotin-ATTCCTCAACCCTATCCTAAACTCTAT-3'; the sequence of the sequencing primer GPVI-S is 5'-AATATAGATTAGGTTTTAGTAGG-3'. A pyrosequencing method is adopted for sequencing, the methylation and non-methylation proportions of a CpG island in a target region are efficiently detected, the methylation level of the GPVI promoter region is evaluated, and the methylation level can be used as an earlyindex for myocardial infarction.
Owner:HENAN UNIV OF CHINESE MEDICINE
Method for diagnosing alzheimer's disease using-soluble gpvi
InactiveUS20130217050A1Good reproducibilityDiagnosed noninvasivelyDisease diagnosisBiological testingBiological activationBody fluid
Provided are an agent for noninvasively and easily diagnosing Alzheimer's disease, a method for diagnosing Alzheimer's disease through the measurement, and a measurement kit therefor. The present invention relates to a reagent for measuring soluble GPVI (sGPVI) in a human body fluid; an agent for specifically diagnosing Alzheimer's disease, said agent comprising a reagent for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid; and a method for specifically diagnosing Alzheimer's disease, said method comprising a step for measuring the concentration of sGPVI in a collected human body fluid and a step for measuring the activation of platelets or coagulation-fibrinolysis system in said human body fluid.
Owner:MOCHIDA PHARM CO LTD
Inhibition of platelet aggregation using Anti-human gpvi antibodies
ActiveUS20190367608A1Rapid and safe and prolongedShorten the counting processPharmaceutical delivery mechanismImmunoglobulins against cell receptors/antigens/surface-determinantsGlycoproteinPlatelet aggregation
The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Owner:UNIV PARIS SACLAY +3
Inhibition of platelet aggregation using Anti-human gpvi antibodies
PendingCN110494447APharmaceutical delivery mechanismImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody SuppressionAntiendomysial antibodies
Owner:ACTICOR BIOTECH +4
Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
ActiveUS20120244152A1Hinder recognitionPrevention of unwanted generation of Fab-antibody complexesPeptide/protein ingredientsGenetic material ingredientsHuman plateletAntibody fragments
The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion pheno-type. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used.
Owner:SANOFI SA
Novel Anti-human gpvi antibodies and uses thereof
ActiveUS20180236071A1Without decreasing platelet countEasy to optimizeImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsGPVIAntibody
Owner:UNIV PARIS SACLAY +3
Method and kits for determining platelet susceptibility to activation in a patient
The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
Antibodies targeting glycoprotein vi
ActiveUS20210214435A1Improve effectivenessImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntibody fragmentsThrombus
The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.
Owner:MORFOZIS AG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com